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Abstract: Conjugates of methotrexate (MTX) and the nucleoside analogs 3-azidodeoxythymidine (AZT), iododeoxyuridine 
(IUdR) and dideoxycytidine (ddC) linked using poly(ethyleneglycol) are presented. In vitro cytotoxicity assays of the 
conjugates against drug resistant ovarian cell line A2780/AD are preformed and comparisons made to such assays performed 
for unconjugated (cocktail) systems. All systems tested were inactive, or had low activity, at 24 h. After 72 hr incubation 
however, the cocktails of MTX and AZT, IUdR or ddC showed high cytotoxicity in the low nanomolar range. The conjugates 
were only very moderately active with IC50 values in the [0.1 to 1.0 mM] range. Conjugation of the antifolate to the nucle-
oside analogs has it seems reduced the activity signiﬁ  cantly when compared to a cocktail of the components, indicating a 
conjugate approach is unlikely to translate into success in vivo. The positive note comes from the observation that by 
combining two of the new conjugates, namely those based on MTX with IUdR or AZT, an IC50 at 24 hours of ∼ [180 μM] 
was produced.
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Introduction
Targeted drug delivery is a rapidly growing ﬁ  eld of chemotherapeutics. The goal of targeted drug delivery 
is to minimize the loss of healthy tissue that occurs during traditional, systemic chemotherapy. The 
ability to selectively target tumours greatly improves a drug’s therapeutic index and lowers the treat-
ment burden on the patient. To achieve this goal, chemotherapeutics are designed to have two (or more) 
major components. One such component is the cytotoxic compound, with the other being the targeting 
agent. This latter moiety has driven the search for agents that will deliver the cytotoxic component to 
unique markers of tumours such as prostate speciﬁ  c membrane antigen or over-expressed folate receptor 
(FR).
1 Indeed, the FR has proven highly successful in targeting studies, beneﬁ  ting from an overexpres-
sion in certain tumor lines and the high binding afﬁ  nity of FR (KD ∼ 0.42 × 10
9 M) for folate.
2
The use of antifolates in cancer therapy has also received considerable attention over several decades 
because of their ability to inhibit folate dependant enzymes. These enzymes are of particular interest in 
cancer chemotherapeutics because they are vital for DNA synthesis. Methotrexate (MTX) (see Fig. 1), 
the most widely used antifolate, interferes with de novo thymine synthesis for example.
3 The primary 
target of MTX is dihydrofolate reductase (DHFR),
4 which is responsible for reducing dihydrogenfolate 
(DHF) to tetrahydrofolate (THF). MTX has also been shown to be an inhibitor of thymidylate synthase
5 
(TS), which catalyses the methylation of uracil to thymine. Antifolates, because of their structural 
similarities with folate, can take advantage of the same delivery pathways as for folate in vivo. There is 
an important caveat for FR however and it is the fact that the FR has an approximately 100-fold lower 
afﬁ  nity for MTX over folate.
6 Using MTX as a successful targeting moiety for the FR then is unlikely.
Delivery of MTX through the reduced folate carrier (RFC) however, coupled with its demonstrated 
anticancer properties, still make this an intriguing system for incorporation into new bioconjugates. The 
RFC has a high afﬁ  nity for MTX with a Km of 5–10 μM (Folate; Km = 200–400 μM).
7 Using this mode 
of cellular entry and combining MTX with systems that contrast, but complement, its intracellular 
activity (e.g. interfering with DNA synthesis/replication) may provide new systems whose synergism 
provides activity greater than the sum of its parts.
The complementary system we decided to investigate, in combination with MTX, was that of 
nucleoside analogs. We chose nucleosides because of their potency in vivo. Both MTX and nucleosides 20
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analogs suffer from general systemic delivery and 
a lack of more speciﬁ  c targeting (relative to the 
FR). This usually requires greater doses be admin-
istered (when feasible and appropriate) to acquire 
the necessary cytotoxic concentration. This often 
makes these compounds unsuitable for use on their 
own. Nucleoside analogs have been primarily 
examined for their ability to inhibit reverse tran-
scriptase, with 3-azidodeoxythymidine (AZT) 
(Fig. 2) being one of the most notable examples.
8 
Nucleoside analogs, as with antifolates, also have 
the ability to inhibit enzymes necessary for de 
novo thymidine synthesis, such as thymidylate 
synthase (TS) and thymidylate kinase (TK). 
Alternatively they can be incorporated into a 
growing strand of DNA, and either cause strand 
termination, or produce a kink in the DNA that 
prevents replication.
9
We were further inspired to conjugate these 
systems by reports that combinations of MTX and 
5-ﬂ  urouracil
10 or AZT
11 overcame resistance to 
MTX in certain cell lines. Our aim for this work 
then was to compare and contrast, and investigate 
possible synergy in, MTX and nucleoside cocktail 
and conjugate systems.
The hypothesis was that the conjugated systems 
would provic greater toxicity, especially at earlier 
time points, than the simple mixed systems. Both 
the mixed and conjugated systems should provide 
some degree of synergistic enzyme inhibition 
Figure 1. Folic acid (vitamin B9) and the antifolate, methotrexate (MTX). Note the methylation of the amine of the p-amino benzoic acid 
moiety and amination of the pterin carbonyl on conversion from folate to MTX.
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Figure 2. Nucleoside analogs 3-azidodeoxythymidin, 5-Iodouracil, and 2’ 3’ dideoxycytosine.21
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(see Fig. 3) but the conjugated systems should 
allow for greater uptake, presumable through the 
reduced folate carrier via MTX, thus ensuring the 
nuceloside analog is also delivered. In additon to 
acting as a spacer, the linker unit chosen, namely 
polyethyleneglycol (PEG), may prevent cellular 
efﬂ  ux of the conjugate after uptake, again providing 
for greater toxicity for the conjugates over the 
cocktails, by increasing the residencey time of both 
the MTX and conjugated nuceloside analog. This 
work focused MTX with three nucleoside analogs, 
namely AZT, iododeoxyuridine (IUdR) and 
dideoxycytidine (ddC) (see Fig. 2).
Results and Discussion
All of the conjugates produced used classic, facile 
‘click’ chemistry. It is necessary, upon conjugation, 
to separate out the two isomers produced. There 
is an active γ-isomer and an inactive α-isomer 
produced by tandem coupling through the α-, and 
γ-carboxylic acids of FA or MTX. The MTX-PEG 
building block (1) was synthesized using a similar 
approach to that used by us for the preparation of 
Folate-PEG-NH2.
12 The desired γ-isomer was 
then puriﬁ  ed by ion exchange chromatography 
using an ANX column. The drugs were synthe-
sized using the same procedure for each of the 
three nucleoside analogs. Brieﬂ  y, MTX was acti-
vated with dicyclohexylcarbodiimide (DCC) and 
N-hydroxysuccinimde (NHS). The activated MTX 
was added to a solution of PEG, and then puriﬁ  ed. 
Previous work on the conjugation of MTX to PEG 
show a racemization of the MTX.
14 The enantio-
mers were not puriﬁ  ed out and were reacted 
together in the subsequent conjugation. The 
nucleoside analogs were directly linked to (γ-1) 
by CDT coupling to create the three conjugates 
studied (see Fig. 4).
Over 24 hours, the conjugated drugs show no 
cytotoxicity over the concentrations tested (up to 
[1 mM]). Combining MTX with AZT or IUdR as 
a cocktail however gave IC50 values at ∼[6 mM] 
at 24 hours, a signiﬁ  cant improvement on that 
noted for conjugates of the same components. 
Interestingly, when MTX was combined with ddC, 
the cocktail did not produce an observed IC50 value 
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Figure 3. Thymidylate synthesis pathway and the enzymes targeted by methotrexate and nucleoside analogs. Enzymes are show in circles 
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at 24 hours, as noted for MTX/AZT and MTX/IUdR. 
Unlike AZT and IUdR, ddC does not inhibit one 
of the primary enzymes of the thymidine synthesis 
pathway, a fact that might explain the lack of syn-
ergism.
Both the cocktails and conjugates of MTX with 
all three nucleoside analogs did however show IC50 
values at 72 hours. At 72 hours the conjugates show 
cytotoxicity in the ∼ [0.20–0.9 mM] concentration 
range. In stark contrast, the cocktails greatly 
affected cell viability, with IC50 values now in the 
low [nM] range.
It is clear that the combinations, rather than the 
conjugations, are far more effective at reducing 
cell viability.
Based on our observed results, we decided to 
see if a cocktail of the two most active conjugates, 
namely (2) and (3), could work in tandem to 
achieve cytotoxicity more akin to the free, mixed 
components. Such a cocktail would be expected to 
have the MTX uptake route, but also increased 
activity because of its putative ability to inhibit 
three of the major enzymes in thymidine synthesis, 
namely DHFR, TS, and TK. The cocktail of (2) 
and (3) shows [uM] activity over 72 hours similar 
to the results observed with each conjugate indi-
vidually and so again far inferior to the combina-
tions of MTX with AZT or MTX with IUdR alone, 
as recorded in Table 1. Importantly, however, over 
24 hours the new cocktail of (2) and (3) achieved 
more signiﬁ  cant toxicity, ∼[0.18 mM]. This is far 
superior to the free components at the same 24 hour 
time point. The individual conjugates (2) and (3) 
did not show toxicity up to [1 mM] over the same 
time frame.
To conﬁ  rm uptake of the conjugates, a ﬂ  uorescent 
analog was synthesized to follow uptake via 
confocal microscopy.
13 After a one hour incubation 
with the ﬂ  uorescent system, the A2780/AD cells 
showed uptake as can be seen in Figure 5. Depth 
scanning at 1 μM per layer conﬁ  rmed the compound 
was localized throughout the cell.
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Figure 4. Nucleoside conjugates of γ-MTX-PEG (1) with AZT (2), IUdR (3), and ddC (4).23
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To glean further insight into the new conjugates, 
(2), (3) and (4) were also screened for DHFR inhi-
bition. The compounds exhibited IC50 values in the 
micromolar range [∼105–400 μM] (see Table 2). 
The compounds all displayed similar inhibition, 
which suggests that the nucleoside analog itself 
does not signiﬁ  cantly contribute to the inhibition 
of DHFR. The results are consistent with DHFR 
inhibition studies reported previously with 
pegylated MTX systems and as with that study the 
conjugates were not as effective as ‘free’ MTX 
alone.
To explain the in vitro results, the stability of 
the compounds was examined. (3) was dissolved 
in phosphate buffered saline at a pH of 7.4, and 
incubated at 37 °C. Time points were taken at 24 and 
72 hours. Over 24 hours, there was no sign of free 
nucleoside. After 72 hours, a peak consistent with 
free nucleoside (conﬁ  rmed by 
1H NMR) appeared 
indicating partial decomposition. While not com-
pletely stable over the time tested, the stability of 
the carbamate linkage could be preventing the 
nucleoside from being released in the cell over the 
earlier time points. This is consistent with previous 
nucleoside conjugate work reported and the obser-
vation that (2) and (3) have a greater toxicity at 
72 hours than the carrier system (1). The delay in 
the release could explain the discrepancies between 
the conjugated and the unconjugated systems.
Conclusion
Looking at three nucleoside analogs that have 
different modes of activity, we have created a series 
of conjugates and compared them to the activity 
of their ‘free’ constituents. All compositions tested 
were inactive, or had low activity, after 24 h. After 
72 h incubation time, the non-conjugated mixtures 
of MTX and AZT, IUdR or ddC show a very 
high cytotoxic potential in the low nanomolar 
range, while the conjugates are only very moder-
ately active with IC50 values from [0.1 to 1 mM]. 
Conjugation of the antifolate to the nucleoside 
analogues has then reduce the activity signiﬁ  cantly 
when compared to a cocktail of the components, 
indicating a conjugate approach is unlikely to 
translate into success in vivo. The conjugation does 
lower MTX’s ability to inhibit DHFR in the cell 
free assay. However, the PEG conjugate (1) has a 
Table 1. In vitro IC50 [mM] values against the A2780/AD 
overian cancer cell line.
Drug 24 hours 72 hours
MTX 10 7 ± .9
AZT 10 8 ± 1
MTX + AZT 6 ± 1 1 × 10
−6
MTX + IUdR 6 ± 1 1 × 10
−6
MTX + ddC 10 1 × 10
−6
1 1 0.700 ± .1
2 1 0.43 ± .03
3 1 0.211 ± .1
4 1 0.960 ± .080
2 + 3 0.184 ± .072 0.101 ± .014
Figure 5. Drug uptake monitored by confocal μ microscopy in ovarian cell line A2780/AD (10X, 100X).24
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greater activity in vitro, so it appears that conjugating 
MTX is not the the major cause of the decrease in 
activity. Another potential cause then might be 
found by focusing instead on the nucleoside. 
Conjugation of the 5’-hydroxy group, necessary 
for activity in the body, would likely decrease 
affinity for target enzymes (TK for instance). 
Earlier work with a folate-nucleoside (AZT) con-
jugate system however showed increased activity 
over unconjugated nucleoside in vitro.
12 A reason 
for the lack of synergism then might be the physical 
conjugation itself. Being connected, it may prevent 
the two drugs from inhibiting both of the target 
enzymes at the same time, requiring signiﬁ  cantly 
higher doses to achieve this result. It is unlikely 
that the conjugates are not escaping the lysosome 
given the distribution observed in the confocal 
microscopy studies repported herein.
The positive note from this work comes from 
the observation that by combining two of the new 
conjugates produced, namely (2) and (3), an IC50 
at 24 hours of ∼[180 μM] was observed. Given 
this value is better than that noted even for the free 
componants at this same time point, this is a sig-
niﬁ  cant step in the right direction for these systems 
and one we are currently exploring further.
Experimental Section
Chemicals and equipment
3’-Azido-3’-deoxythymidine (AZT) was purchased 
from Toronto Research Chemicals, Toronto, 
Canada. Methotrexate (MTX) was purchased from 
Axis Chemicals. 5-Iodo2’-deoxyuridine (IUdR), 
2’,3’-Dideoxycytidine (ddC), Polyetheylene 
glycol (PEG), Dicyclohexylcarbodiimide (DCC), 
N-hydroxysuccinimde (NHS), l,l’-Carbonyl-di-
(l,2,4-triazol) (CDT), carbonylditetrazole and 
sodium phosphate were purchased from Sigma as 
the highest purity available. Chromatography grade 
DMSO (Sigma) was dried through a column of 
molecular sieves (4 A, Sigma) under dry nitrogen. 
Water was distilled and deionised to 18.6 MW 
using a Barnstead Diamond RO Reverse Osmosis 
machine coupled to a Barnstead Nano Diamond 
ultrapuriﬁ  cation machine. An Agilent 1100 HPLC 
with manual injection and automated fraction 
collector was ﬁ  tted with a Zorbax C18 analytical 
column (4.6 (i.d) × 30 mm) to follow reactions and 
a semi-prep (10 (i.d) × 200 mm) column for puri-
ﬁ  cation. Nuclear magnetic resonance was carried 
out on a Bruker 300 MHz machine. Solvent sup-
pression and exponential transformation typically 
gave optimum results for NMR spectra containing 
Polyethyleneglycol. Electrospray mass spectrom-
etry was performed on a Shimadzu LCMS-2010A 
system at a cone voltage of 5 kV. RPMI media 
(folate free) was purchased from the American type 
culture collection (ATCC). PeniStrep antibiotic 
cocktail and Cell stripper were purchased from 
Sigma Aldrich. A Thermo Multiscan EX 96-well 
plate reader was used at a wavelength of 450 nm. 
Adriamycin resistant ovarian cell line A2780/AD 
was a generous gift from the Fox chase cancer 
centre, Philadelphia. Human blood serum was 
purchased from SIGMA.
HPLC puriﬁ  cation
(2), (3), (4) and (5) were puriﬁ  ed by reverse phase 
gradient HPLC on a Zorbax semi-prep C18 column 
(9.4 × 250 mm; Agilent Technologies) with 
initially 100% water run up to 10% acetonitrile 
over 5 minutes then up to 50% acetonitrile over 
12 minutes then held for 5 minutes with a ﬂ  ow rate 
of 2 ml/min.
Synthesis of γ-MTX-PEG-NH2 (1)
Methotrexate (0.392 g, 0.8 mmol), DCC (0.196 g, 
0.9 mmol) and NHS (0.112 g, 0.9 mmol) were 
dissolved in 3 ml of DMSO and stirred overnight 
in a dark room. The white precipitate (reaction 
by-product of dicyclohexyl urea) formed was 
removed by vacuum ﬁ  ltration. Bis-Amine PEG 
2000 (200 mg, 0.1 mmol) was dissolved in 2 ml 
of dry DMSO. The activated MTX was added drop 
wise and stirred for 6 hours under. (1) was puriﬁ  ed 
by LPLC as described previously. Brieﬂ  y, (1) was 
precipitated out with a hexane/acetone mixture, 
and then redissolved in water to give a 20 mg/ml 
concentration. Using a 20 ml ANX column (GE) 
the reaction was loaded with pure water at a ﬂ  ow 
Table 2. Inhibition of dihydrofolate reductase.
Compound IC50 [μ, M]
1 200
2 152
3 394
4 178
MTX 1.025
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rate of 0.4 ml/min. After the ﬁ  rst peak was eluted 
the column was washed with 10% 0.1 M ammo-
nium until the ﬁ  rst major peak was eluted, and then 
increased the concentration of ammonium acetate 
to 60% until the desired peak eluted. The yield was 
30% of the desired isomer. 1H NMR (D2O): δ 8.32 
(s, 1H, 7H), 7.82 (d, 2H, 2’, 6’ H) 7.05 (d, 2H, 3’H, 
5’H), CH 3.3–3.8 (PEG) 2.92 (m, 2H). MALDI-
TOF MS m/z Expected 2436, and found centred 
at 2349 [M + H]+.
Synthesis of γ-MTX-PEG-AZT (2)
AZT (16 mg, 0.05 mmol) and CDT (10 mg, 
0.06 mmol) were dissolved in 1 ml of DMSO and 
stirred for 4 hours at room temperature. (1) (20 mg, 
0.008 mmol) was dissolved in 200 ml of DMSO 
and added to the solution. The reaction was then 
stirred overnight at room temperature under nitro-
gen. The solvent was removed in vacua and the 
remaining yellow solid was re-dissolved in water. 
(2) was isolated by HPLC with a retention time of 
14.3 min. Yield is 40% based on 1. 1H NMR (D2O): 
δ 8.62 (s, 1H, 6 H), 8.32 (s, 1H, 7H), 7.82 (d, 2H, 
2’, 6’ H) 7.05 (d, 2H, 3’H, 5’H), 5.99 (t, 1H, 1’ CH) 
4.48 (m, 2H), 4.47 (m, 1H) 3.5–3.8 (PEG), 2.92 
(m, 2H) 2.33 (b, 4H), 1.33 (s, 3H). MALDI-TOF 
MS m/z Expected 2736 and found centred at 
2718 [M + H]+.
γ-MTX-PEG-IUdR (3)
1H NMR (D2O): δ 8.65 (s, 1H, 6-H), 8.32 (s, 1H, 
7-H), 7.72 (d, 2H, 2’, 6’-H) 6.91 (d, 2H, 3’, 5’-H), 
6.2 (t, 1H, 1’ -H) 4.48 (m, 2H), 4.47 (m, 1H) 
3.5–3.8 (PEG), 2.92 (m, 2H) 2.33 (m, 4H) MALDI-
TOF MS m/z Expected 2813 and found centred at 
2800 [M + H]+.
γ-MTX-PEG-ddC (4)
1H NMR (D2O): δ 8.32 (s, 1H, 7-H), 7.82 (m, 3H, 
2’, 6’-H, 6-H) 7.22 (d, 1H), 7.05 (d, 2H, 3’, 5’-H), 
5.99 (t, 1H, 1’ CH, 7.64 (m, 3H), 5.90 (t, 1) 4.48 
(m, 2H), 4.47 (m, 1H) 3.5–3.8 (PEG), 2.92 (m, 2H) 
2.33 (s, 3H). MALDI-TOF MS m/z MALDI-TOF 
MS m/z Expected 2675 and found centred at 2651 
[M + H]+.
Synthesis of γ-MTX-PEG-ReBQAV (5)
Re(CO)3-BQAV (10 mg, 0.0152 mmol), prepared 
by previous literature protocol
13, was activated 
with CDT (3 mg, 0.0182 mmol) in DMSO for 
1 hour at 37 °C. The reaction was allowed to cool 
to room temperature and compound (1) (20 mg, 
0.0082 mmol) was added, and allowed to react 
overnight. The product was precipitated out 
with acetone/hexane mixture then puriﬁ  ed with 
HPLC conditions above with a retention time of 
16.8 minutes. 
1H NMR (300 MHz, D2O): 8 = 8.62 
(s, 1H), 8.43 (d, 2H), 8.02 (d, 2H), 7.98 (d, 2H), 
7.82 (m, 4H), 7.64 (m, 4H), 7.53 (d, 2H), 3.5–3.8 
(PEG) 2.48 (t, 2H), 2.92 (m, 2H), 2.06 (br, 2H), 
1.77 (m, 2H) MALDI-TOF MS m/z MALDI-TOF 
MS m/z Expected 3122 and found centred at 3050 
[M + H]+.
In vitro, cell free DHFR inhibition assay
The DHFR calorimetric assay was purchased from 
Sigma Aldrich, and was performed according to 
instructions. Briefly, DHFR was mixed with 
inhibitor and NADPH.
Dihydrofolate was then added to the mixture 
and the absorbance at 330 nm was monitored over 
2.5 minutes. The average slope was compared to 
the average slope of a control that did not have any 
inhibitor present. The percent of control was plotted, 
and a ﬁ  t using a power regression line used.
In vitro cytotoxicity (WSK-8) assays
The proliferation of exponential phase cultures of 
A2780/AD cells was assessed by colorimetric 
assay (WSK-8). In brief, cells were plated onto a 
96 well microtiter plates at 5,000 cells per well. 
After a 24 hour incubation period to facilitate 
adherence, the RPMI media was removed and 
replaced with 100 or 200 μL of fresh media con-
taining the different concentrations of drug. The 
cells were then incubated for 1 or 3 days at 37 °C 
at 95% humidity and 5% CO2. The media was then 
removed, and replaced with 100 μL fresh media 
containing 10% WSK-8 dye. The plates were 
incubated for 1.5 hours and subsequently measured 
at 450 nm with a 96-well plate reader. A non-linear 
curve ﬁ  tted to the concentrations tested was used 
and the data plotted using Origin software. Each 
concentration was run in triplicate, and drug 
was tested 3 times. MTX has a greater afﬁ  nity 
(100 times) for the reduced folate carrier (RFC) 
over folate, and has a 100 fold less afﬁ  nity for the 
FR than oxidized folate.
11 To fully investigate the 
uptake and cytotoxicity of the conjugates produced, 
IC50 values were obtained in folate deficient 
media.26
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Confocal microscopy experiments
The A2780/AD ovarian cancer cells (150,000 cells/dish) 
were plated on 356 × l00 mm vented dishes. The 
cells were incubated at 37 °C overnight in FA-free 
RPMI 1640 media. To each plate was added [10 mm] 
of (5) (1 mL volume) the plate then incubated for 
1 hour. The drug was then removed, and the cells 
were washed with 50 mm phosphate buffered saline 
(PBS; 3 × l mL). The cells were then washed with 
acidiﬁ  ed saline solution (3 × l mL; 3.4 mm NaCl, 
pH 3.0) and ﬁ  xed with ice-cold MeOH.
Stability study
(3) was dissolved in PBS buffer 1 at pH 7.4 in a 
concentration of [l mM]. The solution was incu-
bated at 37 °C for 24 and 72 hours. Samples from 
the solution were examined using the HPLC 
Eclipse XDB C18 analytical column (4.6 × 159 mm; 
Agilent Technologies). The method conditions 
were the same as the puriﬁ  cation with a ﬂ  ow rate 
of 0.7 ml/min.
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